Avidity Biosciences (RNA) said Monday that topline data from the phase 1/2 EXPLORE44 trial of del-zota to treat Duchenne muscular dystrophy showed "consistent, statistically significant improvements in dystrophin, exon skipping and creatine kinase."
The biopharmaceutical company said del-zota also demonstrated favorable safety and tolerability in the dose cohorts. It also said it will present the data at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference this week.
Shares of Avidity Biosciences were up 2.9% in recent premarket activity.
Price: 32.00, Change: +0.89, Percent Change: +2.86
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。